MorphoSys AG
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$12.0M
Doctors Paid
20
Transactions
2,774
2023 Total
$5.4M
Payment Breakdown by Category
Research$12.0M (99.3%)
Consulting$78,907 (0.7%)
Travel$1,291 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.0M | 2,732 | 99.3% |
| Consulting Fee | $78,907 | 39 | 0.7% |
| Travel and Lodging | $1,291 | 3 | 0.0% |
Payments by Type
Research
$12.0M
2,732 transactions
General
$80,198
42 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | $4.4M | 0 | 552 |
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | $2.4M | 0 | 694 |
| An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study | $1.6M | 0 | 42 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | $742,169 | 0 | 793 |
| A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | $715,247 | 0 | 73 |
| A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND | $332,523 | 0 | 31 |
| A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) - B-MIND | $322,183 | 4 | 140 |
| A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND | $321,468 | 0 | 49 |
| realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy (realMIND) | $234,470 | 0 | 78 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | $193,474 | 0 | 3 |
| realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients | $123,053 | 0 | 71 |
| A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - L-MIND | $110,787 | 3 | 54 |
| A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined with Idelalisib or Venetoclax in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Brutons Tyrosine Kinase (BTK) Inhibitor | $98,064 | 0 | 18 |
| A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) B-MIND | $91,327 | 2 | 71 |
| A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) | $74,820 | 0 | 2 |
| The REAL-MIND study is a multicenter, observational study that will collect data on treatments and outcomes for patients in the US with relapsed or refractory diffuse large B-cell lymphoma not receiving autologous stem cell transplant who are starting second- or third-line therapy | $62,657 | 0 | 9 |
| The relation between lines of therapy response rate and time dependent endpoints in relapsed and refractory DLBCL | $52,070 | 0 | 1 |
| A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | $39,435 | 0 | 8 |
| A Phase Ib, Open-Label, Multicentre Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) (MINDway) | $36,525 | 0 | 6 |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | $30,603 | 0 | 33 |
| AN OBSERVATIONAL RETROSPECTIVE COHORT STUDY OF SYSTEMIC THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL), TO COMPARE OUTCOMES TO THOSE FROM TAFASITAMAB + LENALIDOMIDE IN THE L-MIND STUDY | $12,223 | 0 | 3 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Diagnostic Radiology | $78,652 | 3 | $26,217 |
| Hematology & Oncology | $54,872 | 9 | $6,097 |
| Internal Medicine | $14,542 | 3 | $4,847 |
| Hematology | $10,920 | 2 | $5,460 |
| Medical Oncology | $7,628 | 2 | $3,814 |
| Specialist | $870.00 | 1 | $870.00 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. William Corse, D.o, D.O | Diagnostic Radiology | Doylestown, PA | $42,339 | $0 |
| Bruce Berlanstein, M.d, M.D | Diagnostic Radiology | Baltimore, MD | $31,179 | $0 |
| Christopher Flowers, M.d, M.D | Hematology & Oncology | Houston, TX | $17,390 | $0 |
| Francis Giles, M.d, M.D | Hematology & Oncology | San Antonio, TX | $10,000 | $0 |
| John Burke, Md, MD | Hematology & Oncology | Aurora, CO | $8,171 | $0 |
| Dr. Ross Levine, Md, MD | Internal Medicine | New York, NY | $7,891 | $0 |
| Nilanjan Ghosh, Md, MD | Medical Oncology | Charlotte, NC | $6,900 | $0 |
| Dr. Elizabeth Brem, Md, MD | Internal Medicine | Orange, CA | $5,781 | $0 |
| Andrew Evens, Do, Ms, DO, MS | Hematology | Boston, MA | $5,529 | $0 |
| Haifaa Abdulhaq, Md, MD | Hematology | Fresno, CA | $5,391 | $0 |
| Ira Smalberg, Md, MD | Diagnostic Radiology | Santa Monica, CA | $5,133 | $0 |
| Pierluigi Porcu, M.d, M.D | Hematology & Oncology | Philadelphia, PA | $4,968 | $0 |
| Dr. Mazyar Shadman, Md,Mph, MD,MPH | Hematology & Oncology | Seattle, WA | $4,833 | $0 |
| Umar Farooq, Md, MD | Hematology & Oncology | Iowa City, IA | $4,326 | $0 |
| Amir Fathi, M.d, M.D | Hematology & Oncology | Boston, MA | $3,000 | $0 |
| Daniel Persky, M.d, M.D | Hematology & Oncology | Tucson, AZ | $1,734 | $0 |
| Dr. Nakhle Saba, Md, MD | Specialist | Baton Rouge, LA | $870.00 | $0 |
| Dr. Jason Westin, M.d, M.D | Internal Medicine | Houston, TX | $870.00 | $0 |
| Mr. Jason Chandler, M.d, M.D | Medical Oncology | Germantown, TN | $727.50 | $0 |
| Grzegorz Nowakowski, M.d, M.D | Hematology & Oncology | Rochester, MN | $450.00 | $0 |
Ad
Top Products
- MONJUVI $4.4M
Payment Categories
- Consulting $78,907
- Travel & Lodging $1,291
- Research $12.0M
About MorphoSys AG
MorphoSys AG has made $12.0M in payments to 20 healthcare providers, recorded across 2,774 transactions in the CMS Open Payments database. In 2023, the company paid $5.4M. The top product by payment volume is MONJUVI ($4.4M).
Payments were distributed across 6 medical specialties. The top specialty by payment amount is Diagnostic Radiology ($78,652 to 3 doctors).
Payment categories include: Consulting ($78,907), Research ($12.0M), Travel & Lodging ($1,291).